Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sato Pharmaceutical Co. Ltd.

www.sato-pharmaceutical.com

Latest From Sato Pharmaceutical Co. Ltd.

Verrica's Phase III Success Paves Way For Filing Of New Cantharidin Formulation VP-102

After reporting positive pivotal data for VP-102 in the contagious skin disease molluscum, Verrica is looking forward to a 2020 launch, with plans to price for broad access.

Clinical Trials Research & Development

Pipeline Watch: Top-Line Data For Reslizumab, Erenumab And Biosimilar Rituximab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

OTC Recalls: Children's Allergy Tablets, Eye Care Products

Standard Homeopathic's recent recall of its Hyland’s teething tablets was designated class I, indicating a reasonable probability of serious adverse health consequences or death, FDA notes in May 31 update to its recalls database.

Consumer Recalls
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Dental & Oral Products
  • Dermatology
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Sato Pharmaceutical Co. Ltd.
  • Senior Management
  • Seiichi Sato, Pres. & CEO
  • Contact Info
  • Sato Pharmaceutical Co. Ltd.
    Phone: (3)5412-7310
    AHC Building 1-5-27 Moto-Akasaka
    Minato-ku
    Tokyo, 107-0051
    Japan
UsernamePublicRestriction

Register